Tomahawk, WI 03/27/2014 (Basicsmedia) – While Pfizer Inc. (NYSE:PFE) got some bad news when its Celebrex patent was invalidated by a U.S. court, it is seeing good progress on many other fronts. Pfizer has sued an Indian generic drug manufacturer to protect the profits from its blockbuster ED therapy Viagra, which is attracting many generics manufacturers.

A Strong Drug Pipeline

Pfizer has reported success for its experimental drug Bococizumab — or RN316 — in reducing LDL-C cholesterol in a Phase 2b study involving at-risk patients for cardiovascular events. This belongs to a new class of treatments for patients whose high cholesterol level isn’t well controlled by traditional statin therapy.

It has also reported success for PROFILE 1014, which is a Phase 3 study of ALK-inhibitor Xalkori (crizotinib), in meeting its primary goal of significantly prolonging progression-free survival for previously untreated patients with advanced non-squamous non-small cell lung cancer (NSCLC). This establishes Xalkori as an appropriate first-line as well as second-life therapy for use among patients who have a mutation in the ALK gene. This will boost revenue for Pfizer from Xalkori which already generates about $360 million for the company.

With other cancer medications in the pipeline, Pfizer Inc. (NYSE:PFE) hopes to become a major player in oncology.

It has reported one more success in meeting primary end point targets with Phase 3B results for its Genotropin medication in very young children who are born small for their gestational age.

Vaccine Power

Its Investigational Vaccine Candidate Bivalent rLP2086 has received ‘breakthrough therapy’ designation from the U.S. Food and Drug Administration as a potential prevention of meningococcal disease due to Neisseria meningitidis serogroup B.

The company is expecting approval for Prevnar-13, its pneumococcal vaccine for all adults aged 65 and older. If the drug is approved for adults 50 and older, that will translate to even higher revenue for Pfizer.

Jet Lag Therapy?

Pfizer Inc. (NYSE:PFE) is also collaborating with the University of Manchester in England on a new jet-lag therapy. This will take five to 10 years to bring to the market but should be big business considering the millions of jet-setters who suffer from jet-lag.

DISCLAIMER: This content is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.